New Study Links Pfizer’s Bextra, Similar to Vioxx, to Heart Attacks
“This is a time bomb waiting to go off.”
The data is retrospective, and thus not nearly as robust as the Vioxx data, which was randomized. That being said, a black box warning adds to the bad day Bextra is having, for an association with Stevens-Johnson syndrome.
Pfizer defends the allegations, but it’s not looking good (though admittedly not coming from a medical source): “Things look very bleak for Bextra at the moment,” said Gustav Ando, an analyst at World Markets Research Centre. “I think we can pretty much say goodbye to it.”
We’ll see.
